There is no trick that switches urgency off. The honest answer is that bowel urgency in ulcerative colitis is produced by a physical change in your rectum, a loss of capacity and a gain in sensitivity, and the only intervention with strong evidence behind it is controlling the inflammation that caused that change. Everything else, the kits and the route planning and the slow mornings, reduces the consequences of urgency rather than the urgency itself.
That is not a counsel of despair. It matters enormously because it reframes what you should be asking for. Urgency is measurable, it predicts hard outcomes, it is routinely missed in clinic, and when it outlasts a clear colonoscopy there are specific tests and treatments that most people are never offered. This article is about all of that, rather than about drinking more water and avoiding spicy food.
The short answer: treat the rectum, then treat the leftovers
Stopping urgency happens in two stages, and people get stuck because they try to do the second one first.
Stage one is inflammation control. While the rectal lining is inflamed, no amount of planning changes the underlying physics, and the studies below show exactly why. Stage two is what is left over once inflammation is genuinely gone, which for a substantial minority of people is still quite a lot. That leftover has different causes, different tests and different treatments, and it is where the specific, useful, rarely-offered interventions live.
The most common failure mode is treating stage two symptoms as if they were stage one, which usually means more restriction and more avoidance, or treating stage one as if it were stage two, which means managing around active disease for months while it quietly progresses. Knowing which stage you are in is the single most useful thing this article can give you, and it mostly comes down to whether anyone has measured your inflammation recently. Our guide to knowing whether your ulcerative colitis is flaring covers how to build that picture from scores and calprotectin rather than from feel.
What urgency actually is, and why it is not the same as frequency
Bowel urgency is defined in the UC literature as the sudden or immediate need to have a bowel movement (Dubinsky 2022). That definition matters because it is about the window, not the count. You can open your bowels twelve times a day with plenty of warning each time, or three times a day with ten seconds' notice. Those are completely different lives, and only the second one stops you getting on a train.
This distinction is not academic. When researchers developed the Urgency Numeric Rating Scale, they ran qualitative interviews with 16 people with UC and found bowel urgency was a distinct symptom, not a synonym for stool frequency. In their two-week diary study of 41 patients, average urgency scores correlated highly with patients' own global rating of severity, but only moderately with stool frequency (Dubinsky 2022). In other words, how urgent things feel and how often you go are related but they are not the same measurement.
That is the same gap that makes the standard two-item UC score incomplete. PRO-2 captures stool frequency and rectal bleeding, and those two items do most of the work in trials, but neither of them asks how long you can hold on. We cover what that score does and does not capture in the guide to the PRO-2 score; the short version is that a person can score well on it and still be unable to leave the house.
A thread in r/UlcerativeColitis asking whether urgency ever truly goes away drew a long and unusually precise discussion, where one reply split the question exactly the way a clinician would: is this the "I am about to have an accident" kind, or the "something is happening and I should start moving toward a toilet" kind (r/UlcerativeColitis thread). Those two sensations sit at very different points on the scale, and conflating them is why people get confusing answers about whether their experience is normal.
What is happening in your rectum when you cannot wait
Three changes stack up, and each has been measured directly.
The rectum becomes hypersensitive. In a study using a rectal probe in nine people with UC whose active disease was limited to the rectum and sigmoid colon, compared with 17 healthy volunteers, the patients were hypersensitive to mechanical stretch (Drewes 2006). This is a small study, and the authors describe it as such, but the design is unusually informative because it separated the wall's mechanical behaviour from the nervous system's response.
The muscle is held tight, so there is less room. In the same study, there was no difference in compliance or stiffness between patients and controls, but the hypersensitivity disappeared after the smooth muscle was pharmacologically relaxed. The authors concluded that the smooth muscle in the inflamed rectum is tonically contracted, producing a decreased rectal circumference (Drewes 2006). A smaller reservoir fills faster. That is the mechanical core of urgency.
The threshold for "I need to go" drops. A prospective study of 36 people with active UC and 10 healthy volunteers combined high-resolution anorectal manometry with rectal barostat testing at two time points. Greater endoscopic and histological activity correlated with lower sensory thresholds and with reduced rectal capacity and compliance. Specifically, the Mayo endoscopic subscore correlated inversely with the volume at which people first felt a desire to defecate and with the maximum tolerated volume (Sanchis Martínez 2026). The more inflamed the lining, the less it takes to trigger the alarm.
Put those together and the experience makes sense. The container is smaller, it is stiffer in the sense of holding less before signalling, and the alarm goes off earlier. None of that responds to willpower, which is worth saying plainly to anyone who has been told to relax.
Urgency is measurable, and the number is more useful than you would think
The Urgency Numeric Rating Scale is one question: rate the immediacy of your need to have a bowel movement over the past 24 hours, from 0 (no urgency) to 10 (worst possible urgency) (Dubinsky 2022). It takes seconds, and unlike most research instruments it was built to be used in a clinic room.
Two anchors from the psychometric work make it genuinely usable:
- A 3-point or greater improvement represents a meaningful improvement in bowel urgency.
- A score of 0 or 1 represents the bowel urgency remission threshold, which in the analysis was closely associated with clinical, endoscopic and histologic remission.
Those thresholds come from an analysis of 1,162 participants in a phase 3 trial, where mean urgency scores fell from 6.2 at baseline to 3.7 at week 12 (Dubinsky 2022b). Test-retest reliability was strong, and the scale correlated with quality of life measures while correlating only weakly with the histology score, which is the statistical signature of a measure capturing something the biopsy does not.
A separate group translated and validated the scale in Portuguese in 126 UC outpatients, 49.2% of whom had bowel urgency. Test-retest reliability was again good, and in the subgroup who underwent anorectal manometry the urgency score correlated with the first constant sensation volume on manometry (Guimarães 2026). That is a patient-reported number tracking a physiological measurement, which is about as good as this kind of validation gets.
Note what that trial was: open-label, single-arm, with no control group, in people already selected for having urgency, and funded by Eli Lilly and Company, which makes the drug studied. Single-arm results cannot separate drug effect from regression to the mean or from the effect of being in a trial. The reason to care about it here is not the drug, it is that somebody finally measured deferral time in minutes, which is the unit patients actually live in.
Why urgency deserves more weight than it usually gets
Urgency is not a quality-of-life extra that sits downstream of "real" disease activity. It independently predicts what happens next.
In a study within the IBD Partners patient-powered research network, 632 people with UC were assessed cross-sectionally and then followed for 12 months. After adjusting for clinical variables, rectal bleeding and stool frequency, urgency categorised as "hurry", "immediately" and "incontinence" raised the odds of social impairment (odds ratios 2.05, 2.76 and 7.7 respectively versus "no hurry") and significantly raised the odds of depression, anxiety and fatigue. Over the following year, those same categories raised the odds of colectomy by 1.42, 1.90 and 3.69 (Sninsky 2022). Urgency also predicted hospitalisation and corticosteroid use.
The phrase to hold on to is "after adjusting for rectal bleeding and stool frequency". Urgency was carrying information that the standard two-item score did not.
So when a review describes bowel urgency as underassessed in clinical practice and infrequently included as a trial endpoint despite being associated with higher disease severity, corticosteroid use, hospitalisation and colectomy, that is a fair summary of the position (Dubinsky 2026). That review has authors employed by or consulting for the manufacturer of a UC drug marketed on its urgency data, which is worth knowing while reading its conclusion that urgency measurement should be built into routine care. The underlying observation is still supported by the independent cohort above.
The communication gap, with numbers
If you have ever felt that your clinician treats urgency as a footnote, the survey data backs you up.
In the CONFIDE study, online cross-sectional surveys of 200 US and 556 European patients with moderate-to-severe UC and 200 US and 503 European clinicians found that while over half of clinicians ranked bowel urgency among the top symptoms affecting patients' lives, fewer than a quarter ranked it among the top three influencing their treatment decisions (Travis 2024). Meanwhile 45.0% of US patients and 37.0% of European patients reported wearing protection at least once a week in the past three months because of fear or anticipation of incontinence, and urgency and that fear were the top reasons given for declining social events, work or school, and exercise.
The Japanese survey found something starker still: of the UC patients who self-reported bowel urgency, their treating physicians were unaware of it in 54.5% of cases (Wang 2024). Both CONFIDE and that survey were funded by Eli Lilly and Company, a company with a commercial interest in urgency becoming a treatment target. The finding is consistent across three continents and matches what people report in patient communities, but you should read it knowing who paid for it. The follow-up CONFIDE analysis across the US, Europe and Japan found up to 97% of patients reported emotional impacts from urgency (Rubin 2025b).
The practical implication is not cynicism, it is vocabulary. "Diarrhoea" gets logged as stool frequency. "I have roughly two minutes of warning and I wore protection to this appointment" does not. If you find that hard to raise, our post on getting a doctor to take gut symptoms seriously covers the structural reasons these conversations go wrong and how to escalate when they do.
Stage one: what actually reduces urgency
The interventions with real evidence are the ones aimed at inflammation, and for urgency specifically, at inflammation in the rectum.
Where the disease is matters. Proctitis, disease limited to the rectum, produces urgency out of all proportion to how much bowel is involved, because the rectum is the reservoir. A systematic review of 32 randomised controlled trials in ulcerative proctitis, covering 2,839 participants in induction studies and 334 in maintenance studies, confirmed the role of topical 5-aminosalicylic acid for both inducing and maintaining remission, and found combined topical steroid plus topical 5-ASA more effective than either alone in the trials that compared them (Caron 2022). The review also notes that newer drug classes have not been evaluated in isolated proctitis at all, which is why people with proctitis often feel like an afterthought.
Nobody here is going to tell you what to take. The point is narrower and more useful: rectal therapies exist specifically for the part of the bowel that generates urgency, many people with left-sided or rectal disease are on oral treatment alone, and "would a topical treatment help my urgency" is a legitimate and specific question to put to your IBD team.
The target is the lining, not the symptom score. Current guidance for UC in adults is built around assessing and treating to objective measures of inflammation rather than symptoms alone (Rubin 2025). For urgency that cuts both ways: symptoms can persist after the lining improves, and the lining can be inflamed while symptoms are quiet. We cover the second direction in what a high calprotectin with no symptoms means.
Improving urgency tracks with improving everything else. In the phase 3 LUCENT programme, among patients with baseline urgency of 3 or more, those achieving urgency remission were far more likely to reach quality-of-life remission: 87.3% versus 42.7% at week 12 and 91.4% versus 45.5% at week 52, with parallel improvements in physical and mental component scores, work productivity, fatigue, abdominal pain and nocturnal stools (Long 2024). This is an association within a trial funded by the drug's manufacturer, not proof that fixing urgency causes the rest to improve. But it does mean urgency is a reasonable thing to steer by.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
Stage two: when the scope is clear and the urgency is not
This is where most articles stop and most readers actually live. Here is what the evidence says is going on.
Microscopic inflammation can persist. A study of 100 patients with UC in Taiwan split them by urgency score into urgency-active (above 1) and urgency-remission (1 or below). Endoscopic remission was present in 14% of the urgency-active group and 34% of the urgency-remission group; histological remission in 10% and 36% respectively. In multivariate analysis, a higher histological score and a looser stool form were independently associated with active urgency (Wei 2025). Importantly, the authors also note that urgency persisted in some people despite endoscopic or histological remission and normal stool form. This study reported no external funding and declared no conflicts of interest, which in this literature is unusual enough to be worth saying.
The mechanics may not fully recover. In the prospective barostat study, symptoms improved after treatment but a subset stayed symptomatic: 32.3% still had faecal incontinence, 54.8% still had urgency and 51.6% still had tenesmus at four to six months. Critically, barostat parameters remained altered compared with healthy controls including in patients who achieved histological remission (Sanchis Martínez 2026). Thirty-six patients is small and four to six months is not long, so this is a signal rather than a settled fact. But it is the clearest published answer to "does urgency truly go away", and the answer is: often it improves a lot, sometimes slowly, and the underlying organ may not return entirely to baseline. The same barostat work underpins our guide to tenesmus in ulcerative colitis, which covers the empty-trip problem this creates when you try to count bowel movements.
The rectum may have become hypersensitive in its own right. In 19 people with UC in remission compared with 17 controls, rectal perception measured by barostat was increased, and rectal perception correlated with IBS-like symptoms. Mucosal mast cell numbers were higher in the remission group (228 versus 163 per 100 crypts), more of those mast cells sat close to nerve endings (58% versus 38%) and more were degranulating (40% versus 16%) (van Hoboken 2011). This is a small mechanistic study from 2011 and the correlation reported between perception and symptoms was implausibly high for the sample size, so treat the direction as informative and the precise numbers as fragile.
IBS-type symptoms are common on top of UC. A meta-analysis of studies in IBD remission found IBS-type symptoms in roughly a third of people, and this remains true when remission is confirmed objectively (Fairbrass 2020). Urgency is a normal part of that picture, and our guide to ulcerative colitis symptoms while in remission covers the rest of it and what to get checked first.
The pelvic floor may be the problem. This is the most under-recognised item on the list. In a study of 50 UC patients in documented remission or mild activity who had persistent defecatory symptoms, high-resolution anorectal manometry was performed on everyone, and the authors concluded that defecatory disorders persist at the quiescent stage and warrant evaluation (Abdel Aty 2025). In an older series of 30 IBD patients with persistent defecatory problems despite clinical improvement, all but one met manometric criteria for dyssynergia (Perera 2013). That series was small, weighted toward Crohn's disease (23 of 30) and toward constipation rather than urgency, and only 30% of those completing biofeedback had a clinically significant improvement in their quality-of-life score, so it is suggestive rather than conclusive.
Pelvic floor behavioural treatment: the evidence, honestly
Of everything in stage two, this has the most encouraging results and the weakest study designs, and both halves of that sentence matter.
In a consecutive series of 40 IBD patients in remission with constipation or faecal incontinence despite drug therapy, 35 completed gut-directed behavioural treatment including pelvic floor muscle training, with a median of two sessions. Among those with faecal incontinence, 77% rated themselves "much better" or "very much better", and improvement occurred regardless of diagnosis, previous perianal fistulae, colorectal surgery, presence of an ileoanal pouch or past obstetric trauma (Khera 2019).
A prospective study by the same group in 34 patients with quiescent IBD found 21 of the 29 who completed treatment (72%, or 62% of all those enrolled) reported moderate or substantial improvement, with significant gains in symptom scores, IBD-specific quality of life and illness perception. General quality of life and anxiety and depression scores did not change significantly, and pelvic floor ultrasound measures did not correlate with how much better people said they felt (Khera 2022).
Their systematic review found only two randomised controlled trials, four retrospective case series and one prospective study meeting criteria. Pooling descriptively, pelvic floor muscle training improved symptoms in 20 of 25 (80%) patients with faecal incontinence and 51 of 76 (68%) with evacuation difficulty. The authors state plainly that the studies were limited by small numbers, study design, methodological quality and lack of long-term follow-up (Khera 2019b). They also report a null: pelvic floor muscle training before stoma closure in people with an ileoanal pouch did not appear to reduce the risk or severity of faecal incontinence afterwards.
So the honest framing is: this is a low-risk, non-drug option with consistently positive but largely uncontrolled results, an unblinded patient-rated primary outcome in the largest series, and no long-term data. It is worth asking about, particularly if you are in objective remission and still running for toilets. It is not a proven treatment.
The study that cuts against the self-management story
If this article were selling you a programme, it would stop before this section. It should not.
IBD-BOOST was a multicentre randomised controlled trial in the UK testing a digital, interactive, facilitator-supported cognitive behavioural self-management intervention against care as usual for fatigue, pain and faecal urgency or incontinence. It recruited 780 participants from 4,449 invited, of whom 524 (67%) were female, and randomised them 1:1 for six months. It was funded by the National Institute for Health and Care Research, a public funder, not by industry.
It missed both primary endpoints. Disease-specific quality of life showed an adjusted mean difference of -1.67 (95% CI -4.13 to 0.80, p=0.19) and the global rating of symptom relief an adjusted mean difference of 0.44 (95% CI -0.56 to 1.44, p=0.39). The authors' conclusion is unambiguous: IBD-BOOST did not statistically significantly improve either outcome compared with care as usual (Moss-Morris 2025). A complier-averaged causal effect analysis did find a difference among people who actually used it, but that is a secondary analysis in a trial that missed its primaries, and it is not evidence the programme works.
The parallel process evaluation is the interesting part. Interviews with 30 participants before and 28 after found high satisfaction, continued use of the strategies and self-reported improvements in symptom understanding and quality of life, while the platform's own analytics showed low adherence. The paper's title says it out loud: the process evaluation findings contradict the trial results (Czuber-Dochan 2025).
Both things can be true. People can find an intervention genuinely useful and a trial can still show no average benefit, because "I understood my symptoms better" and "my quality-of-life score moved" are different outcomes. But if you are deciding where to spend limited energy, a large, publicly funded, properly randomised trial reporting a null result is the more reliable signal, and it deserves to be stated as a null rather than spun.
Anxiety, avoidance, and the loop that tightens the window
The psychological layer is real, it is measurable, and it is not the same as being told it is all in your head.
A latent profile analysis nested within that same 780-person trial identified three symptom profiles: moderate (50%), high (40%) and severe (10%). Diagnosis and faecal calprotectin were not associated with which profile someone fell into. Female gender, comorbidity, time since diagnosis and IBS-type symptoms were. So were depression, anxiety, negative symptom perceptions, and all-or-nothing and avoidance behaviours, each of which significantly increased the relative risk of high or severe profile membership after controlling for clinical, inflammatory and demographic factors (Wileman 2025).
Two cautions. This is cross-sectional, so it cannot say which came first, and the sample was people who had already rated their symptom impact at 5 or more out of 10 to enter the trial, which is a high-burden group by design. But the finding that calprotectin did not sort people into profiles while avoidance behaviour did is hard to ignore.
The mechanism people describe in threads matches. A recurring theme in r/UlcerativeColitis is that the further you are from a toilet, the more you feel you need one, and that the fear itself brings the sensation on (r/UlcerativeColitis thread). Several people in the urgency thread describe what they call a lingering fear after a long flare, where the disease has settled but the vigilance has not. Nobody in those threads is claiming their colitis was anxiety. They are describing a second problem sitting on top of the first.
Where the world shrinks to places with known toilets, the pattern is the same one that drives avoidance in other gut conditions, and it responds to the same graded approach. Our post on anxiety about leaving the house with gut symptoms covers safety behaviours and graded exposure in detail; the important caveat for UC is that graded exposure is appropriate for anticipatory avoidance, not for symptoms driven by active inflammation. Do not try to expose your way through a flare.
The practical layer: what people actually do
None of this reduces inflammation. All of it reduces the cost of urgency, which is not nothing when the cost is your job, your degree or your birthday plans.
Know your deferral time in minutes. Everything else follows from this one number. Ten minutes and ninety seconds are different planning problems.
Scout the toilet before you commit. In the boat trip thread, one of the most useful replies simply pointed out that many fishing boats have a small toilet and it was worth asking (r/UlcerativeColitis thread). Ask the question before you decline the invitation.
Build a morning buffer if mornings are your worst window. Several people describe deliberately giving themselves an extra hour or two at home before leaving, on the basis that their bowel is most active early. That is unverified as a strategy, but it is low cost and widely described. Our guide to why mornings are the worst with ulcerative colitis explains why that window exists and why it tends to close by late morning.
Carry the kit. The kit people describe is consistent: a full change of clothes and underwear, wipes, sealable or scented bags, hand sanitiser, something for odour, and protective underwear if it helps. Given that 45.0% of US patients in CONFIDE reported wearing protection at least weekly because of anticipated incontinence (Travis 2024), this is a majority-adjacent experience, not an extreme one.
Tell one person. Repeatedly in these threads, what changed an outing was not a medicine, it was being with people who would not make it a crisis.
Plan the exit. Knowing in advance how you would leave, and having said so to someone, removes most of the dread that makes the window feel smaller than it is.
For travel specifically, including toilet-access schemes and what to carry across borders, our guide to travelling with urgent bowel symptoms goes further than we can here. For the workplace version of the same problem, including what to disclose and what adjustments look like, see keeping a job with a chronic gut condition.
On anti-diarrhoeal medicines specifically, here is exactly what I could and could not verify. They are widely used in chronic diarrhoea generally (Singh 2026), and many people with UC take them with their team's knowledge. The long-standing caution about using them in severe active colitis rests on the concern that slowing the bowel could contribute to toxic megacolon. When I searched for the evidence behind that caution, what exists is old case reports, and the one I could identify most clearly is a 1990 letter reporting loperamide-related toxic megacolon in Clostridium difficile colitis, not in ulcerative colitis (Walley 1990). I was able to confirm that record and its title but not to read the letter's text, and I did not find a randomised trial or a guideline statement I could read in full that settles the question for UC. So the accurate position is: this is a decision for your IBD team, who know how active your disease is, and not one to make from a forum thread in either direction.
A worked example: two people, both scoring 6
Both rate their urgency as 6 out of 10 over the past 24 hours. The number is the same. Almost nothing else is.
| Person A | Person B | |
|---|---|---|
| Story | Diagnosed 8 months ago, first flare settling on treatment | 7 years in, urgency never fully resolved after a long flare |
| Stool form | Bristol 6 to 7 most days | Bristol 4, formed |
| Bleeding | Occasional streaks | None for two years |
| Last calprotectin | Not done since diagnosis | 42 two months ago |
| Last scope | 8 months ago, Mayo 2 | 6 months ago, Mayo 0, biopsies normal |
| Deferral time | Under a minute, all day | 2 to 3 minutes, worst in the morning and after coffee |
| What the evidence points to | Ongoing inflammatory activity as the likely driver | Post-inflammatory rectal change, possible pelvic floor or IBS-type overlay |
| Reasonable next ask | Calprotectin now, review of treatment, whether rectal therapy is appropriate | Referral for anorectal physiology testing and pelvic floor behavioural treatment |
| What would be a mistake | Managing around it with kit and planning for another six months | More dietary restriction, or accepting "your scope is clear, nothing more to do" |
Person A's situation maps onto the Taiwanese finding that looser stool form and histological activity independently predict active urgency (Wei 2025), and onto the cohort evidence that urgency predicts hospitalisation, steroids and colectomy (Sninsky 2022). Person B's maps onto the persistence of altered rectal mechanics after histological remission (Sanchis Martínez 2026) and onto the defecatory-disorder literature (Abdel Aty 2025).
Same score, opposite next steps. That is the argument for measuring more than one thing.
What to track so the next appointment goes differently
You do not need an elaborate system. You need three fields and a date, because those are what turn an adjective into a number a clinician can act on.
- Urgency 0 to 10, once a day, for the past 24 hours. That is the validated question (Dubinsky 2022), and a 3-point change is the meaningful one.
- Deferral time in minutes on your worst episode of the day. This is what the newer trial measures used, and it is the number that maps onto your actual life (Danese 2026).
- Stool form and bleeding, because those are what your team is already scoring, and because stool form independently predicted urgency in the Taiwanese cohort (Wei 2025).
Add a one-word note on what you avoided that day. Over a month, "skipped gym, left work early, cancelled dinner" is the single most persuasive thing you can put in front of a clinician who is deciding whether to escalate, because it converts a symptom into a functional impairment. Clairop is built for this kind of logging, taking a spoken note in seconds and turning weeks of entries into something you can hand over at an appointment. Whatever you use, the format matters more than the tool: our guide to preparing a symptom record for your doctor covers what clinicians actually read and what gets ignored.
One more thing worth tracking, if fatigue is also in your life: urgency and fatigue cluster together, and in the latent profile analysis they travelled in the same symptom groups (Wileman 2025). Our post on fatigue that persists in remission covers the overlapping workup.
Myths about urgency in ulcerative colitis
"If you have urgency you are not in remission." This is the most common reply in the community threads, and it is half right in a way that matters. Clinical remission definitions do generally require symptom resolution, and persistent urgency should prompt a look for inflammation. But the prospective barostat data show altered rectal function persisting in people with confirmed histological remission (Sanchis Martínez 2026), and the Taiwanese study explicitly reported urgency persisting despite endoscopic or histological remission (Wei 2025). Telling someone in documented remission that their urgency proves they are still flaring adds fear without adding information.
"Nothing can be done if your scope is clear." The defecatory disorder, pelvic floor and hypersensitivity literature exists precisely for this group (Khera 2019b, Perera 2013). The evidence is not strong, but "no trial-grade evidence" is not the same as "nothing to try".
"Urgency is just a quality-of-life issue." It independently predicted hospitalisation, corticosteroid use and colectomy within 12 months in 632 people (Sninsky 2022).
"If you fail one biologic you will fail them all." This appears in the teenager's thread as received wisdom. It is not something this article can adjudicate for any individual, and it is contradicted by the routine clinical practice of switching drug classes after non-response. Take it to your IBD team rather than treating it as settled.
"Not eating is the safe way to get through an outing." People describe multi-day fasting in these threads, sometimes for a week. During active colitis that adds a nutritional risk on top of an inflammatory one, and several people in the same threads noted that it made their symptoms worse rather than better once they did eat. If food timing is part of your planning, that conversation belongs with an IBD dietitian. We cover the general principle of eating during active disease, and why restriction started in a flare tends to persist afterwards, in what to eat during a flare.
"Urgency and frequency are the same thing." They correlate only moderately, which is precisely why a separate measure was developed (Dubinsky 2022).
A number I could not reconcile
One of the sources here disagrees with itself, and rather than pick the quotable reading, here is the detail.
A cross-sectional study of 290 UC patients (mean age 50.3) reported faecal incontinence in 13.8% and severe faecal incontinence in 5.9%. Its results state that complete mucosal healing, mucosal healing and clinical remission were each independently inversely associated with faecal incontinence, which reads straightforwardly: less inflammation, less incontinence. It also reports that active total colitis was independently and positively associated with faecal incontinence (adjusted OR 2.51, 95% CI 1.22 to 5.18) and with severe faecal incontinence (adjusted OR 3.95, 95% CI 1.38 to 11.85). But the abstract's conclusion sentence says "disease activity was independently inversely associated with fecal incontinence", which points the opposite way to both of those findings (Hanayama 2026).
I could not obtain the full text to resolve this, so I am not using that paper's conclusion for anything. The most likely benign explanation is a wording slip in the conclusion, since the direction in the results and in the odds ratios is internally consistent. The usable finding, which agrees with the rest of the literature here, is the specific one: active extensive colitis carried roughly two and a half times the odds of faecal incontinence, and the disease extents other than total colitis were not associated with it regardless of activity. That last detail is genuinely interesting, because it suggests how much colon is involved matters as well as how inflamed it is.
When to see a doctor promptly
Urgency on its own, when it is new, worsening, or not settling on your current treatment, is a reason to contact your IBD team rather than to cope. That is the practical read of urgency independently predicting hospitalisation, steroid courses and colectomy within a year (Sninsky 2022).
See a doctor promptly if you have any of these:
- New or increasing blood in your stool, or blood where there was none
- More than six bloody stools a day, especially with fever, a racing heart or feeling faint
- Severe or constant abdominal pain, abdominal swelling or distension, or vomiting
- Fever, night sweats or feeling systemically unwell alongside gut symptoms
- Unexplained weight loss, or being unable to keep fluids down
- Symptoms that wake you from sleep at night
- Signs of anaemia: breathlessness, unusual fatigue, dizziness, pallor
- Symptoms starting for the first time after age 50, or a family history of bowel cancer or IBD, if you have not yet been assessed
- Any new symptom outside your gut that you have not had checked
Severe colitis can progress quickly, and toxic megacolon, perforation and severe dehydration are recognised emergencies in this disease that need urgent hospital assessment (Goyal 2026). If you have been told to go to hospital and are putting it off because you have been admitted before, that history is a reason to go sooner, not later.
The honest bottom line
There is no reliable way to switch urgency off on demand, and any page promising one is selling something. What the evidence supports is narrower and more useful.
Urgency comes from a rectum that holds less and signals earlier, and that change tracks with inflammation, so inflammation control is the intervention that matters most. Urgency is independently predictive of worse outcomes, which makes it worth escalating rather than accommodating. It is measurable in one question and in minutes of deferral time, and those numbers travel better into a consultation than "it is bad". It commonly outlasts a clear scope, sometimes for months, and when it does there is a specific set of next steps, anorectal testing and pelvic floor behavioural treatment, with positive but methodologically weak evidence behind them.
And the one large, publicly funded randomised trial of a digital self-management programme aimed squarely at this symptom did not beat usual care on either primary outcome, however much its participants liked it. That is a null result, and it stays a null result in the summary as well as in the body.
What you can do this week: put a number on it, put a deferral time on it, write down what it cost you, and take that to whoever manages your UC. Not because tracking treats anything, but because the surveys are clear that urgency is being under-asked about, and a page of specifics is harder to skip past than a symptom nobody named out loud.
